Exchange Traded Concepts, LLC Janux Therapeutics, Inc. Call Options Transaction History
Exchange Traded Concepts, LLC
- $4.74 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding JANX
# of Institutions
207Shares Held
50.6MCall Options Held
158KPut Options Held
697K-
Ra Capital Management, L.P. Boston, MA10.4MShares$377 Million8.99% of portfolio
-
Janus Henderson Group PLC London, X03.56MShares$130 Million0.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.52MShares$128 Million7.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.06MShares$111 Million0.3% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$85.3 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.52B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...